Comparative Pharmacology
Head-to-head clinical analysis: TREXALL versus XELODA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TREXALL versus XELODA.
TREXALL vs XELODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, preventing the conversion of folic acid to tetrahydrofolate, thereby inhibiting DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and release of adenosine.
Prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, incorporates into RNA and DNA, leading to cell death.
Oral: 7.5-15 mg once weekly; subcutaneous: 7.5-15 mg once weekly for rheumatoid arthritis; may be increased up to 25-30 mg weekly based on response and tolerability.
Capecitabine 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles.
None Documented
None Documented
Terminal elimination half-life is 3-10 hours; for high-dose methotrexate, half-life is 8-15 hours. Clinically, monitoring at 24, 48, and 72 hours is standard to guide leucovorin rescue
Capecitabine: 0.65-0.85 h; 5'-DFCR: 0.9-1.1 h; 5'-DFUR: 0.75-1.0 h; 5-FU: 0.75-1.1 h. Terminal half-life of 5-FU is short, requiring continuous dosing for sustained exposure.
Renal excretion of unchanged drug accounts for 80-90% of elimination; biliary/fecal elimination is minor (<10%)
Renal (95.5% as metabolites; 26.1% as parent drug and metabolites, primarily 5'-DFCR, 5'-DFUR, and FBAL); fecal (< 3%)
Category C
Category C
Antimetabolite
Antimetabolite